Immune reactivation and paradoxical worsening in an HIV-infected tuberculosis patient.
de Lange
Wiel C M
WC
Department of Pulmonary Diseases, University of Nijmegen, The Netherlands. W.delange@ulc.umcn.nl
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005334:Fever / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007107:Immune System / Q000187:drug effects* / Q000382:microbiology / Q000503:physiopathology; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D013902:Radiography, Thoracic; D012008:Recurrence; D013909:Thorax / Q000473:pathology; D016896:Treatment Outcome; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D019562:Viral Load
D000995:Antitubercular Agents; D000998:Antiviral Agents; D011239:Prednisolone